Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Shares Issued
Ratios

Immuneering (IMRX) Cost of Revenue (2020 - 2022)

Immuneering has reported Cost of Revenue over the past 3 years, most recently at $19343.0 for Q3 2022.

  • Quarterly results put Cost of Revenue at $19343.0 for Q3 2022, down 91.17% from a year ago — trailing twelve months through Jun 2023 was $19343.0 (down 96.57% YoY), and the annual figure for FY2022 was $158122.0, down 86.29%.
  • Cost of Revenue for Q3 2022 was $19343.0 at Immuneering, down from $47933.0 in the prior quarter.
  • Over the last five years, Cost of Revenue for IMRX hit a ceiling of $473233.0 in Q4 2020 and a floor of $19343.0 in Q3 2022.
  • Median Cost of Revenue over the past 3 years was $228075.0 (2020), compared with a mean of $233649.2.
  • Biggest five-year swings in Cost of Revenue: surged 34.4% in 2021 and later crashed 91.17% in 2022.
  • Immuneering's Cost of Revenue stood at $473233.0 in 2020, then plummeted by 56.42% to $206221.0 in 2021, then crashed by 90.62% to $19343.0 in 2022.
  • The last three reported values for Cost of Revenue were $19343.0 (Q3 2022), $47933.0 (Q2 2022), and $90846.0 (Q1 2022) per Business Quant data.